OncoNano Medicine Presents Preclinical Data for ON-BOARD™ IL-12 Program at AACR Annual Meeting 2024
OncoNano Medicine to Present Late-Breaking Poster at AACR Meeting 2024
OncoNano Medicine Appoints Kartik Krishnan as Chief Executive Officer
OncoNano Medicine Announces First Patient Dosed in Phase 1 Study Evaluating ONM-501 in Patients with Advanced Solid Tumors and Lymphomas
OncoNano and Regeneron Enter into Clinical Trial Supply Agreement for Use of Libtayo® (cemiplimab) in ONM-501 Study
SOUTHLAKE, Texas--(BUSINESS WIRE)--OncoNano Medicine, Inc. will present positive final results from its Phase 2 study of pegsitacianine, a pH-sensitive fluorescent nanoprobe for enhanced intra-operative visualization of cancer, in a podium presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023. Results of the study show that acidic pH is a viable marker and can be used for tumor targeting by the company’s ON-BOARD™ micelle platform.
SOUTHLAKE, Texas--(BUSINESS WIRE)--OncoNano Medicine, Inc. today announced an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023, taking place June 2-6, 2023 at McCormick Place, Chicago, Illinois.
OncoNano Medicine to Present at the American Association for Cancer Research (AACR) Annual Meeting 2023
SOUTHLAKE, Texas--(BUSINESS WIRE)--OncoNano Medicine, Inc. today announced that its lead clinical development candidate, pegsitacianine, a pH-sensitive fluorescent nanoprobe for image-guided cancer surgery, has received Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) as an adjunct for the visualization of metastatic disease in the peritoneal cavity in patients undergoing cytoreductive surgery.
OncoNano Medicine Announces Pre-Clinical Data for Dual-Activating STING agonist at the Society for Immunotherapy of Cancer (SITC) Annual Meeting